Nuclease– tag –
-
Precision BioSciences Initiates Clinical Trial for ARCUS Nuclease Gene Editing Therapy PBGENE-DMD in DMD
CRISPR Medicine News USA Overview Precision BioSciences has dosed the first patient in its Phase 1/2 clinical trial for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy (DMD). This therapy utilizes two ARCUS nucleases t... -
Comprehensive Review of CRISPR Gene Therapy: Potential Applications and Challenges for Sickle Cell Disease and Beta-Thalassemia
International Journal of Basic & Clinical Pharmacology Global Overview A comprehensive review covered the discovery, mechanism, therapeutic applications, and current limitations of CRISPR-Cas9, a revolutionary genome editing technology t... -
Gene Editing Startup Race Intensifies: CRISPR Therapeutics Leads in Commercialization, Intellia Advances In Vivo Phase 3, Beam Demonstrates Base Editing Versatility Across Human Therapies
New Market Pitch USA Overview A New Market Pitch analysis reveals CRISPR Therapeutics leads in commercialization with approved therapies, while Intellia Therapeutics shows significant progress in Phase 3 in vivo gene editing trials. Beam... -
UC Berkeley’s Doudna Lab Redesigns Minimal CRISPR Nucleases with AI, Revolutionizing In Vivo Delivery
CRISPR Medicine News USA Overview Researchers at UC Berkeley's Innovative Genomics Institute (IGI), including Jennifer Doudna, have published a Science paper detailing an AI-powered technique to minimize and redesign CRISPR nucleases. Th...
1